Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (n/a)
Text and Data Mining valid from 2020-03-02
Received: 29 January 2020
Accepted: 5 February 2020
First Online: 2 March 2020
Ethics approval and consent to participate
: The DSP is a non-interventional, market research project that collects retrospective data, excludes identifiable protected health information, and complies with all relevant market research guidelines and legal obligations. Data were collected in accordance with the European Pharmaceutical Marketing Research Association guidelines, the US Health Insurance Portability and Accountability Act 1996 (HIPAA;ExternalRef removed), the Health Information Technology for Economic and Clinical Health, and all other pertinent regulations in place at the time of the data collection and thus did not require ethics committee approvals [CitationRef removed].
: Not applicable.
: AD has received grants or research support from AbbVie, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer and UCB Pharma, and consulting fees from Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma. VS has received grants and/or consulting fees from AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, Corrona LLC, Crescendo Bioscience, EMD Serono, F. Hoffmann-La Roche Ltd./Genentech, Inc., GSK, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi and UCB, and has served on advisory boards for AbbVie, Amgen, AstraZeneca, BMS, Celltrion, Crescendo/Myriad Genetics, EMDSerono, Genentech/Roche, GSK, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sandoz, Sanofi and UCB. PGC has received speakers’ bureau or consulting fees from Bristol- Myers Squibb, Pfizer and Novartis. RA has received grants or research support from Bristol-Myers Squibb, consulting fees from Bristol-Myers Squibb, Novartis, Pfizer Roche and Eli Lilly. ES & SB are employees of Adelphi Real World; HT and KG are shareholders and employees of Novartis; SJ is a shareholder and employee of Novartis Pharma AG.